{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:57:12Z","timestamp":1790193432764,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The autoantibody profile of primary biliary cholangitis (PBC) includes antinuclear antibodies (ANA) which are detectable by indirect immunofluorescence in more than 50% of PBC patients. One of the two immunofluorescence patterns which are historically considered \u201cPBC-specific\u201d is the so-called \u201cmultiple nuclear dots\u201d (MND) targeting nuclear body proteins such as Sp100, Sp140, Sp140L proteins, promyelocytic leukemia protein (PML) and small ubiquitin-related modifier proteins (SUMO). It has been hypothesized a role of nuclear body protein alterations in immune disorders such as PBC, thus suggesting novel and more refined therapeutic approaches.<\/jats:p>","DOI":"10.1186\/s13223-021-00539-0","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T07:03:09Z","timestamp":1617174189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Autoantibodies to speckled protein family in primary biliary cholangitis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-739X","authenticated-orcid":false,"given":"Alessandro","family":"Granito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Muratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Muratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"1","key":"539_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/erm.11.82","volume":"12","author":"A Granito","year":"2012","unstructured":"Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12(1):65\u201374.","journal-title":"Expert Rev Mol Diagn"},{"key":"539_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/08916930802709133","volume":"42","author":"P Muratori","year":"2009","unstructured":"Muratori P, Granito A, Ferri S, Pappas G, Volta U, Menichella R, Bianchi FB, Lenzi M, Muratori L. Multiple nuclear dots and rim-like\/membranous IgG isotypes in primary biliary cirrhosis. Autoimmunity. 2009;42:224\u20137.","journal-title":"Autoimmunity"},{"issue":"6","key":"539_CR3","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1128\/MCB.19.6.4423","volume":"19","author":"DB Bloch","year":"1999","unstructured":"Bloch DB, Chiche JD, Orth D, de la Monte SM, Rosenzweig A, Bloch KD. Structural and functional heterogeneity of nuclear bodies. Mol Cell Biol. 1999;19(6):4423\u201330.","journal-title":"Mol Cell Biol"},{"key":"539_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ajg.2009.596","volume":"105","author":"A Granito","year":"2010","unstructured":"Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, Bianchi FB, Bloch DB, Muratori P. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:125\u201331.","journal-title":"Am J Gastroenterol"},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"526518","DOI":"10.1155\/2015\/526518","volume":"2015","author":"M Saare","year":"2015","unstructured":"Saare M, H\u00e4marik U, Venta R, Panarina M, Zucchelli C, Pihlap M, Remm A, Kisand K, Toots U, M\u00f6ll K, Salupere R, Musco G, Uibo R, Peterson P. SP140L, an evolutionarily recent member of the SP100 family, is an autoantigen in primary biliary cirrhosis. J Immunol Res. 2015;2015:526518. https:\/\/doi.org\/10.1155\/2015\/526518.","journal-title":"J Immunol Res"},{"key":"539_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/hep.20619","volume":"41","author":"C Janka","year":"2005","unstructured":"Janka C, Selmi C, Gershwin ME, Will H, Sternsdorf T. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology. 2005;41:609\u201316.","journal-title":"Hepatology"},{"key":"539_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","volume":"24","author":"A Granito","year":"2006","unstructured":"Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, Molo DE, C, Lenzi M, Chapman RW, Bianchi FB. . Antinuclear antibodies giving the \u2018multiple nuclear dots\u2019 or the \u2018rim-like\/membranous\u2019 patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24:1575\u201383.","journal-title":"Aliment Pharmacol Ther"},{"key":"539_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","volume":"2","author":"WH Yang","year":"2004","unstructured":"Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol. 2004;2:1116\u201322.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"539_CR9","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1111\/j.1572-0241.2004.41121.x","volume":"99","author":"MM Kaplan","year":"2004","unstructured":"Kaplan MM. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol. 2004;99:2147\u20139.","journal-title":"Am J Gastroenterol"},{"key":"539_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jaut.2006.06.002","volume":"27","author":"R Rieger","year":"2006","unstructured":"Rieger R, Leung PS, Jeddeloh MR, et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun. 2006;27:7\u201316.","journal-title":"J Autoimmun"},{"key":"539_CR11","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1073\/pnas.95.9.4991","volume":"95","author":"VJ LaMorte","year":"1998","unstructured":"LaMorte VJ, Dyck JA, Ochs RL, Evans RM. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci USA. 1998;95:4991\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"539_CR12","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/sj.onc.1204854","volume":"20","author":"T Regad","year":"2001","unstructured":"Regad T, Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene. 2001;20:7274\u201386.","journal-title":"Oncogene"},{"key":"539_CR13","doi-asserted-by":"publisher","first-page":"11133","DOI":"10.1128\/JVI.76.21.11133-11138.2002","volume":"76","author":"N Madani","year":"2002","unstructured":"Madani N, Millette R, Platt EJ, et al. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol. 2002;76:11133\u20138.","journal-title":"J Virol"},{"key":"539_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.it.2020.04.007","volume":"41","author":"I Fraschilla","year":"2020","unstructured":"Fraschilla I, Jeffrey KL. The speckled protein (SP) family: immunity\u2019s chromatin readers. Trends Immunol. 2020;41:572\u201385.","journal-title":"Trends Immunol"},{"key":"539_CR15","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1128\/JVI.01979-15","volume":"90","author":"M Scherer","year":"2016","unstructured":"Scherer M, Stamminger T. Emerging role of PML nuclear bodies in innate immune signaling. J Virol. 2016;90:5850\u20134.","journal-title":"J Virol"},{"key":"539_CR16","first-page":"1123","volume":"26","author":"D Z\u00fcchner","year":"1997","unstructured":"Z\u00fcchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. 1997;26:1123\u201330.","journal-title":"Hepatology"},{"key":"539_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/gut.2003.036558","volume":"54","author":"EI Rigopoulou","year":"2005","unstructured":"Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528\u201332.","journal-title":"Gut"},{"key":"539_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0168-8278(01)00252-5","volume":"36","author":"DP Bogdanos","year":"2002","unstructured":"Bogdanos DP, Baum H, Sharma UC, et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol. 2002;36:14\u201321.","journal-title":"J Hepatol"},{"key":"539_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.it.2009.05.006","volume":"30","author":"C Selmi","year":"2009","unstructured":"Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 2009;30:415\u201320.","journal-title":"Trends Immunol"},{"key":"539_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/cei.13198","volume":"195","author":"A Berg Tanaka","year":"2019","unstructured":"Berg Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary cholangitis. Clin Exp Immunol. 2019;195:25\u201334.","journal-title":"Clin Exp Immunol"},{"key":"539_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.it.2009.05.005","volume":"30","author":"S Kivity","year":"2009","unstructured":"Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity\u2014friends or foes? Trends Immunol. 2009;30:409\u201314.","journal-title":"Trends Immunol"},{"key":"539_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1590-8658(03)00466-3","volume":"35","author":"DP Bogdanos","year":"2003","unstructured":"Bogdanos DP, Baum H, Butler P, et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis. 2003;35:801\u20135.","journal-title":"Dig Liver Dis"},{"key":"539_CR23","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0016-5085(03)00387-1","volume":"124","author":"S Shimoda","year":"2003","unstructured":"Shimoda S, Nakamura M, Ishibashi H, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology. 2003;124:1915\u201325.","journal-title":"Gastroenterology"},{"key":"539_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1600-065X.1998.tb01220.x","volume":"164","author":"JA James","year":"1998","unstructured":"James JA, Harley JB. B-cell epitope spreading in autoimmunity. Immunol Rev. 1998;164:185\u2013200.","journal-title":"Immunol Rev"},{"key":"539_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","volume":"2","author":"CL Vanderlugt","year":"2002","unstructured":"Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2:85\u201395.","journal-title":"Nat Rev Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13223-021-00539-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T07:10:10Z","timestamp":1617174610000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00539-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00539-0","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"7 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients referred to in the manuscript signed a written informed consent form for the purpose of publication of the results and the study was approved by local ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}